Skip to main
INSM

Insmed (INSM) Stock Forecast & Price Target

Insmed (INSM) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Insmed is expected to see continued growth in their respiratory-focused commercial portfolio and clinical pipeline, as well as potential success in their innovative research programs. While there are risks involved, strong second quarter results and adjusted revenue estimates show a promising outlook. INSM's focus on sustainability and responsible practices also aligns with current market trends and could positively impact future performance.

Bears say

Insmed is a biopharmaceutical company with two commercial products in the respiratory therapeutic area. While the recent strong sales and increased guidance for these products is encouraging, the success of the company ultimately depends on the continued execution of these launches and the potential success of their clinical stage programs in other therapeutic areas. However, risks include lack of de-risking data for additional indications and potential challenges in successfully commercializing the products in a competitive market. Therefore, a long-term positive outlook on Insmed's stock is dependent on a combination of factors, including steady revenue growth, pipeline success, and potential acquisition by a larger company.

Insmed (INSM) has been analyzed by 20 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Insmed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Insmed (INSM) Forecast

Analysts have given Insmed (INSM) a Buy based on their latest research and market trends.

According to 20 analysts, Insmed (INSM) has a Buy consensus rating as of Aug 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $209.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $209.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Insmed (INSM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.